Status:
COMPLETED
Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation
Lead Sponsor:
Abbott Medical Devices
Conditions:
Bradycardia
Atrial Fibrillation
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Evaluation of dynamic Atrial Overdrive Stimulation using the AF Suppression Algorithm to prevent atrial tachyarrhythmias in patients with more than 2% Auto Mode Switch Episodes with optimized pacemake...
Detailed Description
Atrial Fibrillation is the most common Heart Rhythm Disorder requiring therapy.
Eligibility Criteria
Inclusion
- indication for dual chamber pacemaker
- documented paroxysmal or persistent Atrial Fibrillation
- P-wave \>1.0 mV in Sinus Rhythm or sufficient detection of AFib
- stable antyarrhythmic therapy
- age \>= 19 years
- written informed consent
- implantation of a Identity DR 5370/5376 or later
- bipolar atrial lead
Exclusion
- permanent AFib
- reversible etiology of AFib
- HYHA II or IV
- Coronary Artery disease with stable angina pectoris
- implanted ICD or planned implantation of a ICD
- cardiac surgery within the last 6 months or planned within 12 months
- live expectancy \< 12 months
- pregnancy
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT01912326
Start Date
July 1 2002
End Date
April 1 2008
Last Update
October 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Bonn AdöR
Bonn, Germany, 53127